ADC Therapeutics SA (ADCT) – Globe Newswire
-
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
-
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
-
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
-
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
-
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
-
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
-
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
-
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
-
ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
-
ADC Therapeutics Provides Business Updates
-
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lympho
-
Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors
-
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
-
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
-
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
-
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
-
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
-
Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO
-
ADC Therapeutics to Participate in September Investor Conferences
-
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
-
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
-
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
-
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
-
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
-
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Pa
-
ADC Therapeutics Announces Evolution of Board of Directors
-
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
-
ADC Therapeutics to Participate in the Jefferies Healthcare Conference
-
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgki
-
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgki
-
Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)
-
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
-
ADC Therapeutics Announces Pricing of Upsized Initial Public Offering
Back to ADCT Stock Lookup
